<i>NAT2</i> and <i>CYP2E1</i> polymorphisms and antituberculosis drug‐induced hepatotoxicity in Peruvian patients

Abstract

We propose that the presence of NAT2 intermediate and CYP2E1 c1/c1 genotype could help in therapeutic drug monitoring, and optimize its therapeutic benefits while minimizing its risk for side effects or toxicity.